Polylite Taiwan Co., Ltd. (1813.TWO) Stock

1813.TWO logo

Polylite Taiwan Co., Ltd.

1813.TWOTaiwan
Healthcare

Company profile

Polylite Taiwan reported revenue of 304.32 million TWD for fiscal year 2025, down 1.8% from fiscal year 2024. Its largest business segment, USA Development Segment, brought in 58% of segment revenue in fiscal year 2025; United States was the largest region with 58%. Our analysis of its filings shows revenue shrinking from 360.45 million TWD in fiscal year 2023 to 304.32 million TWD in fiscal year 2025, 8.1% a year on average.

What stands out

  • It reported a net loss in each of its last 2 fiscal years, after a profit of 11.20 million TWD in fiscal year 2023; the loss widened from 29.30 million TWD in fiscal year 2024 to 47.94 million TWD in fiscal year 2025.

Figures from company filings; latest fiscal year ended December 31, 2025.

About Polylite Taiwan Co., Ltd.

Polylite Taiwan Co., Ltd. processes, manufactures, imports and exports, and sells various lenses, optical instruments, and medical equipment worldwide. Its GIA polycarbonate lenses, including FSV, SFSV, progressive, KID, and polarized lenses. The company was founded in 1982 and is based in Taoyuan City, Taiwan.

Leadership

  • Yunping Lu — Chief Financial Officer
  • Jing Ru Ni — General Manager

How much revenue does Polylite Taiwan make?

Polylite Taiwan reported 304.32 million TWD in revenue for fiscal year 2025, down 1.8% from 309.91 million TWD in fiscal year 2024.

What is Polylite Taiwan's largest business segment?

USA Development Segment, with 177.49 million TWD or 58% of segment revenue in fiscal year 2025. Next: Lens Business Division (40%) and Cloud Division (2%).

Where does Polylite Taiwan make most of its revenue?

United States: 58% of revenue by region in fiscal year 2025, followed by Taiwan (42%).

What companies are similar to Polylite Taiwan?

Listed companies of a similar size in the same industry (targeted healthcare equipment) include Taiwan Biomaterial Co., Ltd. (6649.TWO), NaviFUS Corp. (6872.TWO), Diamond Biotechnology Co., Ltd (6815.TWO), Sunder Biomedical Tech. Co., Ltd. (4115.TWO).

Has Polylite Taiwan made a profit in recent years?

Net income by fiscal year: FY2021, a loss of 13.13 million TWD; FY2022, 6.71 million TWD; FY2023, 11.20 million TWD; FY2024, a loss of 29.30 million TWD; FY2025, a loss of 47.94 million TWD. It reported a net loss in 3 of these 5 years.

Company Information

SectorHealthcare
IndustryTargeted Healthcare Equipment
HeadquartersTaoyuan City, Taiwan
ExchangeTaipei Exchange
TimezoneAsia/Taipei (CST)

Contact & Links

Address
No. 406, Changfa Road, Taoyuan City, 33759
Phone
886 3 385 3934
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Polylite Taiwan Co., Ltd. (1813.TWO)”, data as of Dec 31, 2025, https://dataporium.tech/stocks/1813.TWO

LinkedInLinkedInXXYouTubeYouTube